A new study offers encouraging news for older adults with chronic respiratory conditions who may struggle to access traditional gym-based rehabilitation programs. Researchers found that pulmonary ...

Artificial intelligence is showing promise in improving the detection and management of idiopathic pulmonary fibrosis (IPF), ...

In its second-quarter earnings release, the company said that in July and August 2025 it analyzed interim data from the ...

Consistently tracking KL-6 levels may help predict acute exacerbations in IPF and other types of fibrotic ILDs, a study ...

The FDA has approved Insmed’s brensocatib, the first treatment for non-cystic fibrosis bronchiectasis, a chronic and progressive lung disease affecting about 500,000 people in the U.S. The drug was ...

The U.S. Food and Drug Administration has approved Insmed's daily bronchiectasis pill, brensocatib, which will be sold under ...

Large cohort study finds interstitial lung disease independently increases lung cancer risk across all major subtypes, even ...

Net loss for the three months ended June 30, 2025, was $41.6 million or $0.49 per basic and diluted share, compared to a net loss of $28.7 million, or $0.38 per basic and diluted share, for the three ...

Janet Pope, MD, MPH, discusses screening and diagnostic approaches for interstitial lung disease in patients with systemic ...

After positive trial results for TX45, Tectonic Therapeutic is planning a Phase 2 study to test its effects on blood flow in ...

Phase III data show Hernexeos can elicit a confirmed objective response rate of 48% in patients with HER2-mutated NSCLC who had previously been treated with a directed antibody-drug conjugate.